Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gdansk
Clinical trial register · Poland

Clinical Trials in Gdansk, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca59 Medical University of Gdansk32 Janssen Research & Development, LLC30 Merck Sharp & Dohme LLC27 Hoffmann-La Roche24
Site location
Warsaw1315 Krakow882 Poznan705 Gdansk657 Lodz619
All 264 locations
Target enrolment
to

Trials with a site in Gdansk

657 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bydgoszcz, Warsaw, Gdansk, Elblag, Torun, Wroclaw
2021-07-15
Active, closed
VectivBio AG
Phase 3
158
Bydgoszcz, Gdansk, Lodz, Lublin, Skawina
2021-07-13
Active, closed
Neurocrine Biosciences
Phase 3
103
Gdansk, Rzeszów
2021-06-25
Recruiting
HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children
NCT05009433Pregnancy, Postpartum, Childbirth, Health Status
Gdansk University of Physical Education and Sport
Not applicable
600
Gdansk
2021-06-24
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Gdansk, Otwock, Warsaw
2021-06-24
Active, closed
AstraZeneca
Phase 3
506
Gdansk, Krakow, Opole, Warsaw
2021-06-22
Recruiting
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NCT04498767Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
200
Gdansk, Warsaw
2021-06-10
Active, closed
Bristol-Myers Squibb
Phase 3
681
Biała Podlaska, Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw
2021-05-21
Recruiting
Ipsen
Phase 1/2
240
Gdansk, Katowice, Krakow, Lodz, Oświęcim, Poznan, Sandomierz, Warsaw
2021-04-29
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Biała Podlaska, Gdansk, Katowice, Skorzewo, Torun
2021-04-09
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Lublin, Gdansk, Krakow, Lodz, Skorzewo, Wroclaw
2021-04-08
Active, closed
Hoffmann-La Roche
Phase 3
751
Bydgoszcz, Gdansk, Kielce, Krakow, Lodz, Oświęcim, Plewiska, Poznan
2021-03-24
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Słupsk, Gdansk
2021-03-22
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Skórzewo, Torun, Wroclaw, Lublin, Brzozów, Gdansk, Katowice, Wałbrzych
2021-03-11
Recruiting
AstraZeneca
Phase 1
304
Gdansk, Krakow, Olsztyn, Tomaszów Mazowiecki, Warsaw
2021-03-09
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Iwaszkiewicza 5, Lublin, Gdansk, Gdynia, Brzozów, Bydgoszcz, Katowice, Krakow
2021-03-09
Active, closed
Celgene
Phase 3
313
Gdansk, Krakow, Lodz, Poznan, Wałbrzych, Wroclaw
2021-02-25
Active, closed
Hoffmann-La Roche
Phase 3
270
Gdansk, Lublin, Olsztyn, Warsaw, Wroc?aw
2021-02-23
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Gdansk, Gliwice, Krakow, Wroclaw
2021-02-23
Active, closed
Sellas Life Sciences Group
Phase 3
127
Bydgoszcz, Gdansk, Gdynia, Kielce, Legnica, Olsztyn, Opole, Słomniki
2021-02-08
Active, closed
AstraZeneca
Phase 1
155
Gdansk, Lodz, Lublin, Warsaw
2021-02-02
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Gdansk, Gliwice, Poznan, Warsaw, Wroclaw
2021-02-01
Active, closed
Hoffmann-La Roche
Phase 2
920
Gdansk, Warsaw
2021-01-18
By invitation
Gdansk University of Physical Education and Sport
Not applicable
120
Gdansk
2021-01-15
Active, closed
Genmab
Phase 3
483
Gdansk, Katowice, Krakow, Lodz, Skorzewo, Wroclaw
2021-01-13
Active, closed
Galderma R&D
Phase 3
500
Bydgoszcz, Chorzów, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2021-01-11
Active, closed
BioNTech SE
Phase 2/3
358
Gdansk, Gliwice, Konin, Wroclaw
2021-01-07
Active, closed
Pfizer
Phase 3
841
Konin, Brzozów, Bytom, Gdansk
2020-12-21
Active, closed
Daiichi Sankyo
Phase 3
1,600
Poznan, Opole, Gdansk, Lodz, Warsaw
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 3
769
Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Lublin, Oświęcim, Plewiska
2020-12-03
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Gdansk, Kielce, Krakow, Lublin, Olsztyn, Otwock, Poznan, Skorzewo
2020-12-02
Active, closed
Hoffmann-La Roche
Phase 3
864
Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Późna, Rzeszów, Szczecin
2020-11-26
Active, closed
AstraZeneca
Phase 3
957
Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw
2020-11-17
Active, closed
Janssen Research & Development, LLC
Phase 1
136
Gdansk, Warsaw
2020-11-13
Active, closed
AstraZeneca
Phase 1/2
702
Bydgoszcz, Gdansk, Gdynia, Grzepnica, Lodz, Torun, Warsaw
2020-11-12
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Bydgoszcz, Elblag, Gdansk, Gdynia, Kielce, Koszalin, Lodz, Radom
2020-11-12
Recruiting
Meril Life Sciences Pvt. Ltd.
Not applicable
988
Krakow, Gdansk, Katowice, Warsaw, Wroclaw
2020-11-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Gdansk, Warsaw
2020-11-03
Active, closed
Provention Bio, a Sanofi Company
Observational
188
Warsaw, Gdansk
2020-10-26
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bydgoszcz, Gdansk, Gdynia, Olsztyn, Poznan, Warsaw
2020-10-13
Active, closed
Acerta Pharma BV
Phase 3
611
Gdansk, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2020-10-08
Active, closed
Hoffmann-La Roche
Phase 3
210
Bydgoszcz, Gdansk, Lublin, Skórzewo, Warsaw
2020-10-08
Active, closed
GlaxoSmithKline
Phase 3
302
Bydgoszcz, Gdansk, Krakow, Lodz, Wroclaw
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bydgoszcz, Gdansk, Gdynia, Olsztyn, Poznan, Warsaw
2020-09-30
Recruiting
Epygenix
Phase 3
150
Gdansk, Krakow, Warsaw
2020-09-15
Active, closed
AbbVie
Phase 3
531
Bydgoszcz, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-09-10
Active, closed
Women's Cancer Study Group GmbH
Phase 3
1,260
Gdansk, Krakow, Warsaw
2020-09-02
Active, closed
AbbVie
Phase 3
330
Piła, Poznan, Krakow, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-08-31
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Gdansk, Poznan, Warsaw
2020-08-25
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw
2020-08-18
Recruiting
Meril Life Sciences Pvt. Ltd.
Observational
200
Gdansk
2020-08-07
Active, closed
Genentech, Inc.
Phase 1
498
Gdansk, Józefów
2020-07-29
Active, closed
AstraZeneca
Phase 3
134
Chęciny, Gdansk, Lodz
2020-07-20
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Gdansk
2020-07-13
Active, closed
AstraZeneca
Phase 3
1,012
Bydgoszcz, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Rzeszów, Torun
2020-07-13
Active, closed
Actelion
Phase 3
935
Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Szczecin, Warsaw, Wroclaw
2020-06-30
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
530
Gdansk, Koszalin, Krakow, Mysłowice, Poznan, Skórzewo, Warsaw
2020-06-29
Active, closed
Sanofi
Phase 3
337
Bydgoszcz, Lodz, Gdansk, Chorzów
2020-06-16
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Gdansk, Gliwice, Poznan, Warsaw
2020-06-12
Active, closed
AstraZeneca
Phase 2
452
Gdansk, Konin, Koszalin, Krakow, Warsaw
2020-06-03
Active, closed
AstraZeneca
Phase 3
805
Gdansk, Lodz, Lublin, Olsztyn
2020-05-05
Active, closed
GlaxoSmithKline
Phase 3
325
Gdansk, Krakow, Torun
2020-04-02
Active, closed
Eli Lilly and Company
Phase 3
261
Gdansk, Warsaw
2020-02-17
Active, closed
BeOne Medicines
Phase 3
955
Bialystok, Brzozów, Bydgoszcz, Chorzów, Gdansk, Gdask, Krakow, Lodz
2020-01-16
Active, closed
Actelion
Phase 3
138
Gdansk, Krakow, Poznan, Warsaw, Wroclaw, Zabrze
2020-01-16
Active, closed
Sperm Selection Strategies and Male-Factor Phenotypes in ICSI
NCT07825584Assisted Reproductive Technology, Assisted Reproductive Technology Outcomes
Center for Reproductive Medicine Bocian
Observational
12,561
Poznan, Lublin, Warsaw, Rzeszów, Bialystok, Gdansk, Katowice, Szczecin
2020-01-02
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Warsaw, Gdansk, Koszalin
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Warsaw, Gdansk, Koszalin
2019-12-19
Recruiting
Trifecta-Kidney cfDNA-MMDx Study
NCT04239703Kidney Transplant Rejection
University of Alberta
Observational
300
Bialystok, Bydgoszcz, Gdansk, Katowice, Poznan, Szczecin, Warsaw, Wroclaw
2019-12-01
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Wroclaw, Lodz, Warsaw, Gdansk, Katowice
2019-11-26
Active, closed
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
NCT04014205Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
DrugOrelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
81
Gdansk
2019-11-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Warsaw, Gdansk, Gdynia, Lodz, Wroclaw
2019-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Gdansk, Poznan
2019-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
790
Poznan, Gdansk, Warsaw
2019-10-28
Recruiting
GlaxoSmithKline
Phase 1/2
184
Gdansk
2019-10-25
Active, closed
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsVusolimogene Oderparepvec·Cemiplimab
Replimune, Inc.
Phase 2
231
Gdansk, Krakow, Warsaw, Wroclaw
2019-10-08
Active, closed
GlaxoSmithKline
Phase 1/2
208
Gdansk, Katowice, Lodz, Lublin
2019-10-07
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Gdansk, Krakow, Lodz, Poznan, Warsaw
2019-09-18
Active, closed
PDC*line Pharma SAS
Phase 1/2
73
Gdansk
2019-09-10
Active, closed
Pfizer
Phase 3
896
Poznan, Wroclaw, Będzin, Bialystok, Gdansk, Gdynia, Jelenia Góra, Lodz
2019-09-05
Recruiting
University Hospital Muenster
Phase 3
683
Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin
2019-08-23
Active, closed
BeOne Medicines
Phase 3
510
Bydgoszcz, Chorzów, Gdansk, Gdask, Gdynia, Krakow, Legnica, Lodz
2019-08-20
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Bialystok, Gdansk, Katowice, Lodz, Opole, Warsaw
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Bydgoszcz, Olsztyn, Biała Podlaska, Gdansk, Krakow, Lodz, Lublin, Poznan
2019-08-09
Active, closed
Exelixis
Phase 3
855
Biała Podlaska, Bydgoszcz, Gdansk, Otwock, Poznan
2019-06-25
Active, closed
Bristol-Myers Squibb
Phase 3
437
Biała Podlaska, Bydgoszcz, Bytom, Gdansk, Poznan, Warsaw
2019-06-21
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
366
Gdansk, Warsaw
2019-06-14
Recruiting
HighLife SAS
Not applicable
120
Gdansk, Katowice, Poznan, Warsaw
2019-05-28
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Bialystok, Bydgoszcz, Chorzów, Gdansk, Katowice, Krakow, Lodz, Poznan
2019-05-08
Active, closed
AstraZeneca
Phase 3
810
Gdansk, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2019-04-16
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Częstochowa, Gdansk, Gdynia, Katowice, Lodz, Poznan, Skórzewo, Warsaw
2019-03-28
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Bialystok, Gdansk, Konin, Lodz, Olsztyn, Opole, Poznan, Tomaszów Mazowiecki
2019-03-21
Active, closed
AstraZeneca
Phase 3
724
Bydgoszcz, Elblag, Gdansk, Katowice, Lodz, Warsaw
2019-03-06
Active, closed
Follow-up in Gynecological Cancer Survivors
NCT03515993Gynecologic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,100
Gdansk
2019-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Bydgoszcz, Gdansk, Gdynia, Lodz, Siedlce, Szczecin, Warsaw, Wroclaw
2019-01-25
Active, closed
Celgene
Phase 3
363
Lodz, Gdansk, Lubin, Poznan, Rzwszow, Słupsk, Wałbrzych, Wroclaw
2019-01-02
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Bydgoszcz, Gdansk, Glogow Wielkopolski, Katowice, Kielce, Lodz, Poznan, Rzeszów
2018-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bydgoszcz, Wroclaw, Ostrołęka, Warsaw, Wieliszew, Bialystok, Gdansk, Gdynia
2018-12-27
Active, closed
AstraZeneca
Phase 1
175
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Lodz, Olsztyn, Tomaszów Mazowiecki, Warsaw
2018-12-27
Active, closed
AstraZeneca
Phase 1/2
243
Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw
2018-12-21
Active, closed
OBI Pharma, Inc
Phase 3
575
Gdansk, Krakow, Lodz, Warsaw
2018-12-05
Active, closed
AstraZeneca
Phase 3
407
Bialystok, Gdansk, Poznan, Tomaszów Mazowiecki, Warsaw
2018-11-27
Active, closed
AstraZeneca
Phase 3
1,063
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Ostrołęka, Poznan
2018-11-16
Active, closed
Janssen Research & Development, LLC
Phase 3
84
Bydgoszcz, Gdansk, Krakow, Olsztyn, Rzeszów, Warsaw
2018-10-29
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Krakow, Wroclaw, Gdansk, Olsztyn
2018-10-04
Active, closed
AstraZeneca
Phase 3
730
Gdansk, Olsztyn, Poznan, Tomaszów Mazowiecki, Warsaw, Wroclaw
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Poznan, Radom
2018-09-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Poznan, Bydgoszcz, Krakow, Warsaw, Rzeszów, Gdansk, Bielsko-Biala, Katowice
2018-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Konin, Poznan, Bydgoszcz, Krakow, Warsaw, Opole, Bialystok, Gdansk
2018-08-21
Recruiting
Celgene
Phase 2/3
1,541
Gdansk, Lublin, Warsaw
2018-07-19
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Bydgoszcz, Gdansk, Krakow, Słupsk, Warsaw, Wroclaw
2018-06-26
Active, closed
Exelixis
Phase 3
837
Warsaw, Gdansk, Mysłowice
2018-06-10
Active, closed
AstraZeneca
Phase 3
1,018
Bialystok, Gdansk, Grudziądz, Koszalin, Piotrkow Trybunalski, Poznan, Warsaw, Wroclaw
2018-05-14
Active, closed
GlaxoSmithKline
Phase 2
237
Brzozów, Chorzów, Gdansk, Krakow, Lublin, Opole, Poznan
2018-05-03
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Jelenia Góra, Katowice, Krakow
2018-04-13
Active, closed
AstraZeneca
Phase 2
273
Dąbrowa Górnicza, Gdansk, Gdynia, Grzepnica, Krakow, Lodz, Olsztyn, Poznan
2018-03-07
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
DrugsEmavusertib·Ibrutinib
Curis, Inc.
Phase 1/2
152
Gdansk, Krakow, Warsaw
2017-12-28
Active, closed
Sanofi
Phase 3
475
Poznan, Lodz, Warsaw, Gdansk
2017-12-07
Active, closed
BeiGene
Phase 3
590
Brzozów, Chorzów, Gdansk, Gdynia, Gliwice, Krakow, Legnica, Lodz
2017-10-31
Active, closed
Hoffmann-La Roche
Phase 3
382
Gdansk, Warsaw
2017-09-20
Active, closed
Paediatric Hepatic International Tumour Trial
NCT03017326Hepatoblastoma, Carcinoma, Hepatocellular
Drugs5Fluorouracil·Sorafenib·Vincristine·Doxorubicin
University of Birmingham
Phase 3
450
Gdansk
2017-08-24
Active, closed
Eli Lilly and Company
Phase 3
5,637
Konin, Poznan, Wroclaw, Lublin, Warsaw, Opole, Gdansk, Gdynia
2017-07-12
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Bialystok, Gdansk, Katowice, Krakow, Lodz, Lublin, Nowy Sącz, Rzeszów
2017-06-26
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Wroclaw, Warsaw, Gdansk
2017-06-26
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Brzozów, Gdansk, Chorzów, Lodz
2017-05-22
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
4,975
Gdansk, Gliwice, Poznan, Warsaw
2017-05-03
Active, closed
Pfizer
Phase 3
296
Gdansk, Poznan, Szczecin, Warsaw
2017-04-27
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Gdansk, Lublin, Poznan, Szczecin, Warsaw
2017-03-07
Active, closed
Acerta Pharma BV
Phase 3
310
Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Woj. Podkarpackie
2017-02-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Gdansk, Mysłowice, Pozman, Słupsk, Warsaw, Wroclaw
2016-12-22
Active, closed
Eisai Inc.
Phase 3
1,069
Gdansk, Lublin, Szczecin
2016-10-13
Active, closed
Philogen S.p.A.
Phase 3
214
Gdansk, Warsaw
2016-07-01
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Gdansk
2016-06
Recruiting
Boston Scientific Corporation
Observational
300
Bydgoszcz, Gdansk, Warsaw
2016-03-07
Active, closed
ReCor Medical, Inc.
Not applicable
282
Gdansk, Warsaw
2016-03
Active, closed
Bayer
Phase 1/2
154
Gdansk
2015-12-16
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Gdansk
2015-12-11
Active, closed
AstraZeneca
Phase 3
1,126
Gdansk, Gdynia, Gliwice, Olsztyn, Otwock, Szczecin, Warsaw
2015-11-02
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
Ostrowiec Świętokrzyski, Wroclaw, Krakow, Katowice, Bialystok, Bydgoszcz, Chorzów, Gdansk
2015-10-15
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Gdansk, Lodz, Opole, Warsaw
2015-08
Active, closed
Acerta Pharma BV
Phase 3
533
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Olsztyn, Opole, Słupsk
2015-07-28
Active, closed
Acerta Pharma BV
Phase 3
535
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Opole
2015-06-26
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Wroclaw, Torun, Gdansk, Słupsk
2014-12-17
Active, closed
Eli Lilly and Company
Phase 3
453
Gdansk, Lodz, Olsztyn, Radom, Szczecin
2014-10-03
Active, closed
AstraZeneca
Phase 1
344
Gdansk, Krakow, Olsztyn, Poznan, Warsaw
2014-08-05
Active, closed
Eli Lilly and Company
Phase 3
669
Gdansk, Bialystok, Lodz
2014-07-22
Active, closed
AstraZeneca
Phase 3
1,837
Gdansk, Grzepnica, Lodz, Olsztyn, Poznan, Warsaw
2014-04-22
Recruiting
Boston Scientific Corporation
Observational
1,500
Bydgoszcz, Gdansk, Warsaw
2014-03-04
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Bialystok, Bydgoszcz, Gdansk, Kutno, Lodz, Poznan, Szczecin, Torun
2013-10-14
Active, closed
AstraZeneca
Phase 3
510
Brzozów, Bydgoszcz, Gdansk, Grudziądz, Krakow, Lubin, Olsztyn, Opole
2013-09-25
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Brzozów, Chorzów, Gdansk, Klinika Nowotworow Ukladu Chlonnego, Krakow, Opole, Słupsk, Wroclaw
2013-09-09
Active, closed
MedImmune LLC
Phase 2
571
Gdansk, Poznan, Szczecin, Warsaw
2013-05-17
Recruiting
CHDI Foundation, Inc.
Observational
35,000
Gdansk, Katowice, Krakow, Poznan, Warsaw
2012-07
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
Gdansk, Warsaw
2010-12
Recruiting
Esteve Pharmaceuticals, S.A.
Observational
500
Bialystok, Gdansk, Lublin, Poznan, Rzeszów, Szczecin
2008-12-09
Active, closed
Genentech, Inc.
Phase 2
378
Gdansk, Kielce, Otwock, Poznan, Rybnik, Warsaw
2008-10-16
By invitation
Copenhagen University Hospital, Rigshospitalet
Observational
23,000
Bialystok, Chorzów, Gdansk, Lodz, Poznan, Szczecin, Warsaw, Wroclaw
1994-01
Rows per page Showing 501–657 of 657
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/gdansk?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 657 of those studies with a site in Gdansk.

How many clinical trials are recruiting in Gdansk?

303 of the 657 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 15 have not yet opened recruitment, 316 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.